T1	PROC 36 51	Estudio abierto
T2	PROC 57 77	evaluar la seguridad
T3	Date 78 91	a largo plazo
T4	CHEM 95 102	BCX9930
T5	PROC 106 117	monoterapia
#1	AnnotatorNotes T5	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T6	LIVB 121 128	sujetos
#2	AnnotatorNotes T6	C0681850; Study Subject; Group
T7	DISO 133 168	hemoglobinuria paroxística nocturna
#3	AnnotatorNotes T7	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T8	Time 160 168	nocturna
T9	CHEM 201 208	BCX9930
T10	DISO 267 302	Hemoglobinuria Paroxística Nocturna
#4	AnnotatorNotes T10	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T11	DISO 327 330	HPN
#5	AnnotatorNotes T11	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T12	PROC 389 425	consentimiento informado por escrito
T13	LIVB 431 438	Mujeres
#6	AnnotatorNotes T13	C0043210; Woman; Population Group | C0242665; wife; Family Group
T14	Neg_cue 439 441	no
T15	PHYS 442 453	embarazadas
#7	AnnotatorNotes T15	C0033011; Pregnant Women; Population Group
T16	Negated 442 453	embarazadas
T17	Neg_cue 454 456	ni
T18	PHYS 457 466	lactantes
#8	AnnotatorNotes T18	C0021270; Infant; Age Group
T19	Negated 457 466	lactantes
T20	LIVB 476 483	sujetos
#9	AnnotatorNotes T20	C0681850; Study Subject; Group
T21	DISO 488 491	HPN
#10	AnnotatorNotes T21	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T22	PROC 516 527	tratamiento
#11	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 536 551	estudio clínico
#12	AnnotatorNotes T23	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T24	CHEM 552 559	BCX9930
T25	LIVB 578 590	investigador
#13	AnnotatorNotes T25	C0035173; Research Personnel; Professional or Occupational Group
T26	Speculated 592 608	se beneficiarían
T27	PROC 615 635	tratamiento continuo
T28	CHEM 640 647	BCX9930
T29	LIVB 657 687	participantes de sexo femenino
T30	LIVB 791 806	mujer no fértil
T31	Neg_cue 797 799	no
T32	Negated 800 806	fértil
T33	LIVB 819 839	mujer en edad fértil
T34	Age 828 839	edad fértil
T35	PROC 863 884	método anticonceptivo
#14	AnnotatorNotes T35	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T36	Duration 938 945	30 días
T38	CHEM 976 983	BCX9930
T39	PROC 1019 1030	abstinencia
T40	LIVB 1053 1075	mujeres en edad fértil
T41	Age 1064 1075	edad fértil
T42	LIVB 1181 1189	paciente
#15	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	LIVB 1199 1230	participantes de sexo masculino
T44	LIVB 1330 1337	hombres
#16	AnnotatorNotes T44	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T45	LIVB 1346 1361	pareja femenina
T46	Age 1365 1376	edad fértil
T47	LIVB 1391 1408	pareja embarazada
T48	PROC 1416 1434	usar preservativos
T49	Duration 1479 1486	90 días
T50	CHEM 1510 1517	BCX9930
T51	LIVB 1534 1540	pareja
#17	AnnotatorNotes T51	C0682323; Partner in relationship; Family Group
T52	PROC 1560 1581	método anticonceptivo
#18	AnnotatorNotes T52	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T53	PROC 1660 1671	abstinencia
T54	LIVB 1788 1796	paciente
#19	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	LIVB 1817 1829	investigador
#20	AnnotatorNotes T55	C0035173; Research Personnel; Professional or Occupational Group
T56	LIVB 1848 1854	sujeto
#21	AnnotatorNotes T56	C0681850; Study Subject; Group
T57	PROC 1890 1904	procedimientos
T58	DISO 1999 2029	afección médica o psiquiátrica
T59	DISO 2069 2104	dependencia al alcohol o las drogas
T60	LIVB 2125 2137	investigador
#22	AnnotatorNotes T60	C0035173; Research Personnel; Professional or Occupational Group
T61	Spec_cue 2149 2154	pueda
T62	Speculated 2155 2182	interferir con la capacidad
T63	LIVB 2187 2193	sujeto
#23	AnnotatorNotes T63	C0681850; Study Subject; Group
T64	Speculated 2226 2244	aumentar el riesgo
T67	LIVB 2272 2278	sujeto
#24	AnnotatorNotes T67	C0681850; Study Subject; Group
T68	DISO 2287 2309	acontecimiento adverso
#25	AnnotatorNotes T68	C0877248; Adverse event; Pathologic Function
T69	DISO 2311 2313	AA
#26	AnnotatorNotes T69	C0000727; Abdomen, Acute; Sign or Symptom | C0002874; Aplastic Anemia; Disease or Syndrome | C0003486; Aortic Aneurysm; Disease or Syndrome | C0004031; Aspergillosis, Allergic Bronchopulmonary; Disease or Syndrome | C0085693; Acute appendicitis NOS (disorder); Disease or Syndrome | C0221014; Reactive systemic amyloidosis; Disease or Syndrome
T70	DISO 2375 2384	toxicidad
#27	AnnotatorNotes T70	C0600688; Toxic effect; Injury or Poisoning
T71	LIVB 2415 2427	investigador
#28	AnnotatorNotes T71	C0035173; Research Personnel; Professional or Occupational Group
T72	LIVB 2457 2463	sujeto
#29	AnnotatorNotes T72	C0681850; Study Subject; Group
T74	PROC 2483 2521	procedimientos específicos del estudio
T75	Neg_cue 2541 2543	no
T76	Negated 2550 2555	mejor
T77	LIVB 2564 2570	sujeto
#30	AnnotatorNotes T77	C0681850; Study Subject; Group
T78	PROC 2586 2616	evaluación de riesgo-beneficio
T79	Neg_cue 2620 2622	no
T80	PROC 2640 2660	tratamiento continuo
T81	Negated 2640 2660	tratamiento continuo
T82	Duration 2652 2660	continuo
T83	LIVB 2665 2671	sujeto
#31	AnnotatorNotes T83	C0681850; Study Subject; Group
T84	Frequency 2681 2687	diario
T85	CHEM 2691 2699	fármacos
#32	AnnotatorNotes T85	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T86	Date 2700 2711	actualmente
T87	CHEM 2737 2749	medicamentos
#33	AnnotatorNotes T87	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T88	Contraindicated 2737 2749	medicamentos
T89	DISO 2790 2807	Hipersensibilidad
#34	AnnotatorNotes T89	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T91	Speculated 2819 2829	sospechada
T92	CHEM 2832 2839	BCX9930
T93	CHEM 2860 2871	excipientes
#35	AnnotatorNotes T93	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T94	DISO 2897 2905	erupción
#36	AnnotatorNotes T94	C0015230; Exanthema; Sign or Symptom | C0302295; Eruptions; Pathologic Function
T96	CHEM 2917 2924	fármaco
#37	AnnotatorNotes T96	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T97	Neg_cue 2925 2927	no
T98	Negated 2931 2941	excluyente
T99	PROC 215 222	estudio
T100	Time 294 302	Nocturna
T102	PROC 762 769	estudio
T103	PROC 1451 1458	estudio
T104	PROC 1617 1624	estudio
T105	PROC 1951 1958	estudio
T106	PROC 2216 2222	ensayo
T66	PROC 920 927	estudio
T73	PROC 1305 1312	estudio
T37	Speculated 2790 2807	Hipersensibilidad
